Under The Auspices of HE Mr. Ghassan Hasbani

Deputy Prime Minister and Minister of Public Health

Naef K. Basile Cancer Institute Breast Center of Excellence
& Clinical and Professional Development Center
& Continuing Medical Education Office

American University of Beirut Medical Center (AUBMC)

5th Annual Beirut Breast Cancer Conference BBCC-5

February 9-11, 2017, Gefinor Rotana Hotel, Beirut, Lebanon

In collaboration with
Lebanese Order of Physicians LOP
Lebanese Society of Medical Oncology LSMO
Lebanese Society of General Surgery SLCG
Lebanese Society of Radiology LSR
American College of Surgeons ACS – Lebanon Chapter
Order of Nurses in Lebanon ONL
Arab Medical Association Against Cancer AMAAC
Message from the Activity Director

It is my great pleasure to welcome you to the Fifth Annual Beirut Breast Cancer Conference BBCC-5, organized by the Breast Center of Excellence, Naef K. Basile Cancer Institute, American University of Beirut Medical Center (AUBMC).

We are pleased to offer you a rich up-to-date multidisciplinary program for the management of patients with breast cancer. BBCC-5 scientific program is designed for Medical Oncologists, Surgeons, Radiation Oncologists, Radiologists, Pathologists, Gynecologists and all interested physicians, Residents, Fellows, and Medical Students as well as Nurses. BBCC-5 includes educational sessions, research posters and oral presentations. In an effort to encourage local cancer research, prizes will be awarded to the selected Best Abstracts and Best Posters.

We have assembled a great panel of speakers and experts to deliver 2017 updates. We will present CME lectures, highlights and updates from major oncology meetings, including St. Gallen, EBCC, ASCO, ESMO, ABC, San Antonio, and published literature. We will also hold three case discussion round table panel sessions and several non-CME satellite symposia. We will also continue the tradition of special scientific talks relevant to both physicians and nurses, and CNE sessions, Pharmacy workshop on oncology pharmacy and NGOs workshop on awareness and fundraising.

BBCC-5 has become an annual tradition and attracts increasing number of participants, faculty, scientific sessions and original research presentations, all with the support of the Lebanese Order of Physicians and Medical Scientific Societies, Lebanese Order of Nursing, Lebanese Order of Pharmacists, Lebanese Society of Medical Oncology, Lebanese Society of General Surgery and other Societies, NGOs and Advocacy Groups, as well as the Arab medical Association Against Cancer (AMAAC).

Finally, on behalf of BBCC-5 Scientific Committee, NKBCI and the CME Office at AUBMC, I wish you a fruitful meeting and a wonderful stay in Beirut and Lebanon.

Nagi S. El Saghir, MD, FACP
Chairperson, BBCC-5
February 2017
General Information

Program Overview
The Breast Center of Excellence of the Naef K. Basile Cancer Institute at the American University of Beirut Medical Center (AUBMC) organizes its fourth Annual Breast Cancer Conference, Beirut BCC5, bringing together the Lebanese Order of Physicians, Lebanese Order of Nurses, Lebanese Order of Pharmacists, various Lebanese and Arab medical associations and non-governmental organizations, and Lebanese and International experts collaborating together in the fight against breast cancer. The program includes updates on breast cancer patient assessment and treatment planning, management of chemotherapy side effects, breast conservative surgery, breast reconstruction, contralateral prophylactic mastectomy, new advances in chemotherapy, anti-HER2 targeted therapy and hormonal therapy and ovarian function suppression, as well as new research abstracts, as well as two pharmacy and NGO workshops.

Objectives
Lebanese and International experts will share knowledge and lessons learnt, discuss novel advances in screening, chemoprevention and loco-regional assessment, patient advocacy and support groups, as well as the latest findings in breast cancer management on surgery, radiation, and systemic therapy.

Target Audience
This annual scientific meeting has been designed for physicians, researchers, scientists, physicians-in-training and medical students, as well as nurses patient advocates. Breast cancer basic and clinical researchers, policymakers, and research promoters/funders are also encouraged to attend.

Venue
This symposium is held at the Gefinor Rotana Hotel, Beirut, Lebanon.

Accreditation
This symposium complies with the Lebanese Order of Physicians Continuing Medical Education and the ANCC guidelines.

American University of Beirut Medical Center is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

The planning committee and presenters declare no conflict of interest, including financial interest in product or company presented, direct research support, or other form of potential bias.
Activity Director

Nagi S. El Saghir, MD, FACP
Professor and Director, Breast Center of Excellence, Naef K. Basile Cancer Institute
American University of Beirut Medical Center
Beirut, Lebanon

Scientific Committee

Hazem Assi, MD
Fouad Boulos, MD
Rebecca El Asmar, RN, MSN
Nagi S. El Saghir, MD (Chair)
Lara Nassar, MD
Eman Sbaity, MD
Arafat Tfayli, MD

Abstract Committee

Hamdy Azim, MD
Nagi S. El Saghir, MD (Chair)
Fady Geara, MD, PhD
Marwan Ghosn, MD, MHHM
Arafat Tfayli, MD

Speakers

Matti Aapro, MD
Dean
Multidisciplinary Oncology Institute
Genolier, Switzerland

Sanaa Al-Sukhun, MD
President of Jordanian Oncology Society
Consultant
Medical Oncology/Hematology
University of Jordan
Amman, Jordan

Jaber Abbas, MD
Clinical Associate Professor
Department of Surgery
American University of Beirut Medical Center
Beirut, Lebanon

Sandrine Atallah, MD
Consultant, Sexual Medicine
Clinical Associate
Obstetrics and Gynecology Department
American University of Beirut Medical Center
Beirut, Lebanon

Mariam Al Sabea, RN
Adult Oncology Outpatient & Quality Coordinator
Short Stay Unit
American University of Beirut Medical Center
Beirut, Lebanon

Hayat Assafiri, PharmD
Senior Attending Clinical Pharmacist
Pharmacy
American University of Beirut Medical Center
Beirut, Lebanon

Ahmad Awada, MD
Professor
Head, Medical Oncology Clinic

Fady Geara, MD
Professor and Chairman
Department of Radiation Oncology
Hatem A. Azim Jr, MD
Associate Scientific Director
Breast Data Center
Jules Bordet Institute
Brussels, Belgium

Ghina Berjawi, MD
Associate Professor
Women's Imaging
Diagnostic Radiology
American University of Beirut Medical Center
Beirut, Lebanon

Fouad Boulos, MD
Associate Professor
Pathology and Laboratory Medicine
American University of Beirut Medical Center
Beirut, Lebanon

Mahmoud ElTamer, MD
Attending Surgeon, Breast Service
Department of Surgery, MSKCC
Professor of Surgery, Weill Cornell Medical College
Memorial Sloan-Kettering Cancer Center
Evelyn H. Lauder Breast Center
New York, USA

Chantal Farra, MD
Associate Professor
Department of Pathology & Laboratory Medicine
American University of Beirut
Beirut, Lebanon

Imad Kaddoura, MD
Assistant Professor
Plastic Surgery

Aya Kabbani, PharmD
Senior Attending Clinical Pharmacist
Pharmacy
American University of Beirut Medical Center
Beirut, Lebanon

Marwan Ghosn, MD, MHHM
Professor and Chairman,
Hematology-Oncology Department,
Faculty of Medicine,
Saint-Joseph University
Beirut, Lebanon

Alissar Ghadar, PharmD
Senior Attending Clinical Pharmacist
Pharmacy
American University of Beirut Medical Center
Beirut, Lebanon

Mouthaffar Rimawi, MD
Medical Director
Smith Breast Center

Nagham Haddad
Physical Therapist
Department of Physical Therapy
American University of Beirut Medical Center
Beirut, Lebanon

Ziad Hamdan, EMBA
Strategy and Management Consultant
Beirut, Lebanon
<table>
<thead>
<tr>
<th>Name</th>
<th>Title/Position</th>
<th>University</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nagi Khouri, MD</td>
<td>MD, Carol Ann Flanagan Professor in Breast Imaging</td>
<td>American University of Beirut Medical Center</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Mazen Kurban, MD</td>
<td>MD, Associate Professor of Dermatology</td>
<td>American University of Beirut Medical Center</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Najla Moufarrij, RN</td>
<td>RN, Adult Oncology Inpatient Registered Nurse IV</td>
<td>American University of Beirut Medical Center</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Deborah Mukherji, MD</td>
<td>MD, Assistant Professor of Internal Medicine</td>
<td>American University of Beirut Medical Center</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Latifa Shihab, RN</td>
<td>RN, Adult Oncology Outpatient Short Stay Unit</td>
<td>American University of Beirut Medical Center</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Wafaa Skaff, RN</td>
<td>RN, Outpatient Services Short Stay Unit</td>
<td>American University of Beirut Medical Center</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Nuhad Yazbick-Dumit, RN, PhD</td>
<td>RN, President, Order of Nurses in Lebanon Associate Professor Hariri School of Nursing American University of Beirut</td>
<td>American University of Beirut</td>
<td>Beirut, Lebanon</td>
</tr>
</tbody>
</table>
### Moderators & Panelists

<table>
<thead>
<tr>
<th>Name</th>
<th>Position or Title</th>
<th>Institution or Hospital</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therese Abu Nasr, MD</td>
<td>Hematologist – Oncologist</td>
<td>Chronic Care Center of Lebanon</td>
<td>Baabda, Lebanon</td>
</tr>
<tr>
<td>Ghassan Abu-Sittah, MD</td>
<td>Assistant Professor</td>
<td>Department of Surgery</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Salim Adib, PhD</td>
<td>Senior Lecturer</td>
<td>American University of Beirut Medical Center</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Georges Aftimos, MD</td>
<td>Professor</td>
<td>Faculty of Medicine</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Walid Ammar, MD</td>
<td>Director General</td>
<td>Ministry of Public Health</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Hazem Assi, MD</td>
<td>Assistant Professor</td>
<td>Medical Oncology</td>
<td>Saida, Lebanon</td>
</tr>
<tr>
<td>Bechara Atiyeh, MD</td>
<td>Clinical Professor</td>
<td>Plastic &amp; Reconstructive Surgery</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Adnan Atallah, MD</td>
<td>Hematology</td>
<td>AinWzain Hospital</td>
<td>Chouf, Lebanon</td>
</tr>
<tr>
<td>David Atallah, MD</td>
<td>Instructor</td>
<td>Obstetrics &amp; Gynecology</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Hamdy A. Azim, MD</td>
<td>Chairman, Professor</td>
<td>Clinical Oncology</td>
<td>Cairo, Egypt</td>
</tr>
<tr>
<td>Fares Azouri, MD</td>
<td>Lecture, Saint Joseph University</td>
<td>Department of Radiation Oncology</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Fatme Baydoun, RN</td>
<td>Nursing Instructor</td>
<td>Nursing National Institute</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Mona Barakat, RN</td>
<td>Oncology</td>
<td>Hammoud Hospital</td>
<td>Saida, Lebanon</td>
</tr>
<tr>
<td>Tarek Berjawi, MD</td>
<td>Chief</td>
<td>Department of Surgery</td>
<td>Beirut, Lebanon</td>
</tr>
</tbody>
</table>

*American University of Beirut, Bechara*
Continuing Medical Education Office

Georges Chahine, MD
Professor
Hemato-Oncology
Hotel Dieu De France
Beirut, Lebanon

Negib Geahchan, MD
Professor
Faculty of Medicine
University of Saint Joseph
Beirut, Lebanon

Michel Daher, MD
Professor
Surgery
Faculty of Medicine
University of Balamand
Balamand, Lebanon

Angela Gebran, RN
Hemato-Oncology
Sahel General Hospital
Beirut, Lebanon

Myrna Doumit, PhD
Associate Professor and Assistant Dean
School of Nursing
Lebanese American University
Byblos, Lebanon

Hady Ghanem, MD
Onco-Hematology
LAU Medical Center-Rizk Hospital
Beirut, Lebanon

Faysal El-Kak, MD
Senior Lecturer
Faculty of Health Sciences
American University of Beirut
Beirut, Lebanon

Mohamad Haidar, MD
Assistant Professor
Department of Radiation Oncology
American University of Beirut Medical Center
Beirut, Lebanon

Fadia Elias, MD
Hematology Oncology
Beirut, Lebanon

Assem Hajj, MD
Associate Medical Director
General Surgery
Clemenceau Medical Center
Beirut, Lebanon

Sami Faddoul, MD
Diagnostic Radiology
Doctors Center
Beirut, Lebanon

Imad Hajj, MD
Medical Director
Surgery
Saint George Hospital University Medical Center
Beirut, Lebanon

Fadi Farhat, MD
Head
Haematology/Oncology Division
Hammoud Hospital
Saida, Lebanon

Sawsan Halabi Ezzeddine, RN
Hematology Oncology
Makasheh general Hospital
Beirut, Lebanon

Anne Franjieh
Fair Face
Khaled Ibrahim, MD
Clinical Assistant Professor of Medicine
Hammoud Hospital University Medical Center
Saida, Lebanon

Amir Ibrahim, MD
Assistant Professor
Department of Surgery
American University of Beirut Medical Center
Beirut, Lebanon

Faek Jamali, MD
Associate Professor of Clinical Surgery
Department of Surgery
American University of Beirut Medical Center
Beirut, Lebanon

Joseph Kattan, MD
Associate Professor
Hematology Oncology
Saint Joseph University
Beirut, Lebanon

Iman Kouatly, RN
Director of Nursing
American University of Beirut Medical Center
Beirut, Lebanon

Zeina Koussa, RN
Nurse Manager
Short Stay Unit
American University of Beirut Medical Center
Beirut, Lebanon

Joseph Makdessi, MD
Clinical Instructor
Faculty of Medicine
University of Balamand
Blamand, Lebanon

Dina Moutran, RN
Hematology
LAU Medical Center-Rizk Hospital
Beirut, Lebanon

Dolly Nasr, MD
Clinical Instructor
Saint Jospeh University
Radiation Oncology
Hotel Dieu de France
Beirut, Lebanon

Lara Nassar, MD
Instructor
Department of Radiation Oncology
American University of Beirut Medical Center
Beirut, Lebanon

Ghassan Ramadan, MD
General Surgery
Hammoud Hospital University Medical Center
Saida, Lebanon

Salim Saba, MD
Assistant Professor
Department of Surgery
American University of Beirut Medical Center
Beirut, Lebanon

Rabih Said, MD
Assistant Professor
Hematology Oncology
Faculty of Medicine
University of Balamand
Blamand, Lebanon
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Department</th>
<th>Institution</th>
<th>City, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ziad Salem, MD</td>
<td>Clinical Associate Professor</td>
<td>Hematology Oncology</td>
<td>American University of Beirut Medical Center</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Eman Sbaity, MD</td>
<td>Instructor</td>
<td>Department of Surgery</td>
<td>American University of Beirut Medical Center</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Muhieddine Seoud, MD</td>
<td>Professor</td>
<td>Department of Obstetrics &amp; Gynecology</td>
<td>American University of Beirut Medical Center</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Ali Shamseddine, MD</td>
<td>Professor</td>
<td>Department of Internal Medicine</td>
<td>American University of Beirut Medical Center</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Mirna Sibaii, RN</td>
<td>Hemato-Oncology</td>
<td>Nabih Berri Governmental University Hospital</td>
<td>American University of Beirut medical Center</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Adel Tabchy, MD</td>
<td>Medical Oncology</td>
<td>Belevue Medical center</td>
<td>American University of Beirut Medical Center</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Arafat Tfayli, MD</td>
<td>Professor</td>
<td>Hematology Oncology</td>
<td>American University of Beirut Medical Center</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Cyril Tohme, MD</td>
<td>General Surgery</td>
<td>Hotel-Dieu de France</td>
<td></td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Ulfat Usta, PhD</td>
<td>Director</td>
<td>Pharmacy</td>
<td>American University of Beirut medical Center</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Ahmad Younes, MD</td>
<td>Oncology</td>
<td>Military Hospital</td>
<td></td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Bassem Youssef, MD</td>
<td>Assistant Professor</td>
<td>Department of Radiation Oncology</td>
<td>American University of Beirut medical Center</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>Rony Zeenny, PharmD</td>
<td>Associate Pharmacy Director</td>
<td>Pharmacy</td>
<td>American University of Beirut Medical Center</td>
<td>Beirut, Lebanon</td>
</tr>
</tbody>
</table>
Thursday, February 9, 2017

12:00 pm: BBCC-5 Registration Open
13:00pm: Opening Welcome: Nagi El Saghir, MD, FACP

13:00-14:30: Advancing Cancer Research in Arab Countries
Moderators: Drs. Hatem A. Azim Jr, Walid Ammar, Fadi Farhat, & Ali Shamseddine

13:00-13:20  BRCA and Panel Mutations in Breast Cancer
Dr. Chantal Farra

13:20-13:40  Clinical Trials in Lebanon and Arab Countries, Africa/ME
Dr. Marwan Ghosn

13:40-14:00  How to Write Research Grants and Obtain Funding
Dr. Hatem A. Azim Jr

14:00-14:20  IRBs and Patient Protection in Lebanon and Arab Countries: Deficiencies and Solutions
Dr. Deborah Mukherji

14:20-14:30  Q & A

14:30- 15:00: Breast Imaging updates: Case presentations
Screen-detected and Early Breast Cancer:
Moderators: Drs. Georges Aftimos, Tarek Berjawi, Sami Faddoul & Eman Sbaity

14:30-15:00  Case Presentations Making a Point
Dr. Nagi Khouri
15:00-16:00: BBCC-5 Opening Ceremony
Moderator: Roula Moawad, Annahar Newspaper

Nagi El-Saghir, President, BBCC-5
Hassan El-Solh, Director, NKBCI
Maroun Abou Jaoude, President, LSGS
Joseph Makdessi, President, LSMO
Antoine Ghossein, President LSR
Nuhad Yazbik-Dumit, President, ONL
Raymond Sayegh, President, LOP
Ghassan Hasbani, Minister of Public Health

16:00-17:10: Screen-detected and Early Breast Cancer:
Moderators: Drs. Georges Aftimos, Tarek Berjawi, Sami Faddoul & Eman Sbaity

16:00-16:20 Recommendations for Excision following Core Needle Biopsy of the Breast: A Contemporary Evidence-Based Approach
Dr. Fouad Boulos

16:20-16:40 Surgery for In-situ Disease
Dr. Mahmoud El-Tamer

16:40-16:55 What’s New in Radiation Therapy for T1 N1 Breast Cancer
Dr. Fady Geara

16:55-17:10 Coffee Break
17:10-18:00: Tumor Board Round Table Case Discussions
Moderators: Drs. Mahmoud ElTamer & Nagi El-Saghir

Panel: Drs. David Atallah, Bechara Atiyeh, Fares Azouri, Fouad Boulos, Georges Chahine, Michel Daher, Fady Geara, Mohamad Haidar, Nagi Khouri, Joseph Makdessi, Lara Nassar, Ghassan Ramadan & Arafat Tfayli

18:00-19:00: Satellite Symposium-Sponsored by Pfizer: (Non-CME):
Palbociclib CDK4/6 Inhibitor in Metastatic Breast Cancer
Moderators: Dr. Joseph Makdessi
Speaker: Dr. Nagi El Saghir

Friday, February 10, 2017

07:30 Registration

08:30-12:00: 5th Oncology Nursing Medical Symposium – Part I
Moderators: Ms. Mona Barakat (Hammoud), Angela Gebran (SGH), Sawsan Halabi Ezzeddine (MGH), Iman Kouatly (AUBMC)

08:30-08:50 Nursing practice regulation as a foundation for nursing specialization
Dr. Nuhad Yazbik-Dumit

08:50-09:10 Novel Targeted Therapies in Breast Cancer Treatment
Dr. Nagi El-Saghir

09:10-09:30 Chemotherapy Administration Guidelines and Patient Education and Side Effect Management
Ms. Mariam Al Sabae

09:30-09:50 “Chemo-brain”: What Do We Know About Cognitive Impairments and How to Manage it.
Ms. Najla Moufarrij
09:50-10:10  Coffee Break

5th Oncology Nursing Medical Symposium – Part II
Moderators: Zeina Koussa (AUBMC), Dina Moutran (LAU-Rizk) & Mirna Sibaii (NBGUH)

10:10-10:30  Lymphedema Detection, Diagnosis, and Management
Ms. Nagham Haddad

10:30-10:50  Sexuality and Intimacy during and after Breast Cancer Treatment
Dr. Sandrine Atallah

10:50-11:10  Survivorship and Quality of Life: The Role of the Nurse
Ms. Latifa Shihab

11:10-11:30  Chemotherapy-Induced Skin and Nail Changes and their Management
Dr. Mazen Kurban

11:30-11:50  Models of Nurse Navigation and Multidisciplinary Care
Ms. Wafaa Skaff

11:50-12:00  Q & A

Participants who attend the 5th Nursing Oncology Symposium will receive 2.9 contact hours

The planning committee and the presenter(s) declare no conflict of interest including financial interest in product or company; direct research support, or other form of potential bias.

American University of Beirut Medical Center Nursing Services Clinical and Professional Development Center is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
12:00 – 13:00  Panel Med/Nursing/NGO/Press DEBATE
Moderator: Nicola Hanna (TL)

Salim Adib, PhD (AUB, School of Public Health)
Walid Ammar, MD (Director General, Ministry of Public Health)
Fatme Baydoun, RN (Lebanese Breast Cancer Foundation)
Rima Dandashi (May Jallad Foundation)
Myrna Doumit, RN, PhD (Lebanese American University)
Faysal El-Kak, MD (AUB, School of Public Health)
Anne Franjieh (FaireFace)
Nagi El Saghir, MD (BBCC-5)
Nuhad Yazbik-Dumit, RN, PhD (President, Order of Nurses in Lebanon)

13:00-14:00  Lunch

14:00-15:30: Neo-adjuvant Therapy:
Moderators: Drs. Hady Ghanem, Faek Jamali, Dolly Nasr & Ahmad Younes

14:00-14:20  Assessment Before, During and After Neo-adjuvant Therapy
Dr. Nagi Khouri

14:20-14:40  Novel Choices of Neo-adjuvant Therapy for HER2-Positive Breast Cancer
Dr. Mouthaffar Rimawi

14:40-15:00  What’s New in Neoadjuvant Therapy for Triple Negative Breast Cancer
Dr. Sana Al-Sukhun

15:00-15:20  Breast Conservation and SLNB After Neoadjuvant Chemotherapy
Dr. Mahmoud El-Tamer

15:20-15:30  Q & A
15:30-17:00: Tumor Boards Round Table Case Discussions
Moderators: Drs. Nagi El-Saghir & Nagi Khouri


17:00-18:00 Non-CME Lecture: Sponsored by an Unrestricted Educational Grant from AstraZeneca: New Trends in Hormonal Treatment in Breast Cancer
Dr. Nagi El Saghir

Saturday, February 11, 2017

Rotana A – C Level

09:00-10:30am: Advances in Breast Cancer Surgery
Moderators: Drs. Ghassan Abou-Sittah, Ahmad Awada, Negib Geahchan & Muhieddine Seoud

09:00-09:20 Management of Breast Cancer during Pregnancy
Dr. Hatem A. Azim Jr

09:20-09:40 Neo-adjuvant Therapy: Indications and Guidelines
Dr. Matti Aapro

09:40-10:00 Long-term Follow-up on Sentinel Lymph Node Biopsy
Dr. Jaber Abbas

10:00-10:20 Surgery for Local and Chest Wall Recurrences
Dr. Mahmoud El-Tamer

10:20-10:40 Post Mastectomy Reconstruction: Immediate and Delayed Options
Dr. Imad Kaddoura
10:40-11:00     Coffee Break

11:00-12:00: Tumor Boards Round Table Case Discussions
Moderators: Drs. Nagi El-Saghir & Mouthaffar Rimawi

Panel: Drs. Therese Abi-Nasr, Ghassan Abou-Sittah, Ahmad Awada, Hatem A. Azim Jr, Mahmoud El-Tamer, Fadia Elias, Marwan Ghosn, Assem Hajj, Imad Hajj, Salim Saba, Ziad Salem, Eman Sbaity & Bassem Youssef

12:00-13:00     **Satellite Symposium-Sponsored by Roche: (Non-CME):** Neoadjuvant Therapy: Recommendations & Controversies
Dr. Jaber Abbas (Surgical Oncology)
Dr. Nagi El Saghir (Medical Oncology)

13:00-14:00     Lunch

14:00-15:00     **Satellite Symposium-Sponsored by Novartis: (Non-CME):** Expanding Horizons: Current and Emerging Treatment Options for Breast Cancer
Dr. Matti Aapro
Dr. Nagi El Saghir

15:00-16:30: What’s New for Next Monday Morning Clinic in Early & Metastatic Breast Cancer
Moderators: Drs. Nizar Bitar, Georges Chahine, Khaled Ibrahim & Joseph Makdessi

15:00-15:20     Standard versus Extended Adjuvant Hormonal Therapy in EBC: New Data and Recommendations for Clinical Decisions
Dr. Matti Aapro
15:20-15:40  First Line and Second Line Therapy in Metastatic Breast Cancer  
Dr. Mouthaffar Rimawi

15:40-16:00  Adjuvant Chemotherapy for Breast Cancer in 2017  
Dr. Hamdy A. Azim

16:00-16:20  Emerging Immunotherapy Data in Breast Cancer  
Dr. Ahmad Awada

16:30-17:30: Oral Presentations and Prizes for selected Winning Best Posters  
(Posters will be on display throughout the conference)  
Moderators: Drs. Matti Aapro, Hatem A. Azim Jr, Marwan Ghosn, Nagi El Saghir, Joseph Kattan & Arafat Tfayli

16:30-16:40  A National Multicenter Prospective Experience with Docetaxel in the Adjuvant Treatment of Early Stage Breast Cancer  
Dr. Elie El Rassy

16:40-16:50  Genetic counseling, screening and risk reducing practices in patients with BRCA mutations in Lebanon  
Dr. Rita Saroufim

16:50-17:00  microRNA Expression in Lebanese Breast Cancer Tissues: A Comparative and Integration Analysis  
Dr. Farah Nassar

17:00-17:10  Awareness campaigns and screening for down-staging of breast cancer in Lebanon  
Dr. Sarah Daouk
Topaz-R Level
Saturday Morning Parallel Session

09:30 - 11:00: Oncology Pharmacy Workshop
Moderators: Dr. Ulfat Usta & Dr. Rony Zeenny

09:30-10:00  Updates in Breast Cancer Management
Dr. Aya Kabbani

10:00-10:30  Breast Cancer Toxicity Management and Prevention
Dr. Hayat Assafiri

10:30-11:00  Drugs Induced Cancer: NIOSH List 2016
Dr. Alissar Ghaddar

11:00-12:00  Workshop: Devising Order Set
Drs. Ulfat Usta, Fatima Ismail, and Maha Wazne

Saturday Afternoon Parallel Session

15:00 - 16:00: NGO Workshop
Facilitator: Ziad Hamdan & Asma Hoballah
Abstracts

Posters and Abstracts Presentation
A national multicenter prospective experience with Docetaxel in the adjuvant
treatment of early stage Breast Cancer
Elie El Rassy¹, Marwan Ghosn¹, Fadi Farhat⁴, Tarek Assi⁴, Georges Chahine¹,³, Fadi Nasr¹,⁴, Fadi Ghassan Haddad¹, Fadi El Karak¹, Joseph Kattan¹,⁵
¹ Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Lebanon
² Department of Medical Oncology, Hammoud Hospital, Saida, Lebanon
³ Department of Medical Oncology, Notre Dame de Secours Hospital, Byblos, Lebanon
⁴ Department of Medical Oncology, Mount Lebanon Hospital, Hadath, Lebanon
⁵ Department of Medical Oncology, Saint Joseph Hospital, Baouchrieh, Lebanon

Introduction Taxanes are amongst the most active and prescribed adjuvant treatment in breast
cancer. Namely Doxetaxel is of great clinical benefit but could be counterbalanced with
intolerable adverse effects. In our study, we evaluate the efficacy and safety of adjuvant
Docetaxel in early-stage breast cancer in the real-life setting.

Methods We conducted a prospective multicenter study that evaluates the efficacy and safety
of Docetaxel-based regimens in patients with early-stage breast cancer. This study collected
data on breast cancer patients treated between July 2007 and December 2012 with a
Docetaxel-based regimen in the adjuvant setting in 5 centers in Lebanon.

Results The study included 698 female breast cancer patients who were receiving adjuvant
Docetaxel-based regimens. Docetaxel monotherapy was administered in 4.2% whilst the
majority of patients received polychemotherapy. Mean disease free survival and overall survival
were 81.2 months (95% CI, 78.2-84.3 months) and 116.7 months (95% CI, 114.8-118.5 months)
respectively and seemed longer in patients that completed the planned adjuvant treatment.
Multiple adverse events were reported and included most commonly asthenia (66.5%),
alopecia (43.4%) and diarrhea (24.2%). Death-events related to drug toxicities did not occur.
Several hematological adverse events were reported during the treatment with anemia being
the commonest.

Conclusion The results of this real-life experience confirm that Docetaxel is effective and well
tolerated in early-stage breast cancer patients.

Keywords: Docetaxel; breast cancer; adverse events; safety; toxicity
Genetic counseling, screening and risk reducing practices in patients with BRCA mutations in Lebanon

Firas Kreidieh, Iman Abou Dalle, Rita Saroufim, Sara Daouk, Nagi El Saghir
American University of Beirut Medical Center, Beirut, Lebanon

Background: 250 Lebanese women with breast cancer at high hereditary risk were studied at the American University of Beirut Medical Center (AUBMC) between 2009 and 2012 and reported in 2015. 14 patients (5.6%) had a BRCA deleterious mutation and 31 (12.4%) had variant of uncertain significance (El Saghir et al., BRCA1 and BRCA2 Mutations in Ethnic Lebanese Arab Women With High Hereditary Risk Breast Cancer. Oncologist. 2015 Apr;20(4):357-364). This is the first large BRCA mutation study in this ethnic Lebanese Arab population where genetic counseling and testing remain scarce. We looked at implementation of further screening/therapeutic measures upon follow-up of those patients.

Methods: We conducted a chart review and phone calls for collection of information on these patients. Patients had consented prior to our initial study to be contacted later on for follow-up. Phone call greetings and questions were approved by IRB. We collected information about genetic counseling, screening methods, breast and ovarian risk reducing surgeries and survival.

Results: 14 patients with deleterious mutations (7 BRCA1 and 7 BRCA2 positive patients) and 31 patients with VUS were included in this analysis. Out of these 45 patients, 7 patients had metastatic breast cancer at initial diagnosis. 2 of these 7 patients had BRCA 1 VUS mutation and 5 patients had BRCA2 VUS mutation. 4 patients were lost to follow. A total of 34 patients, 14 with deleterious mutations and 20 with VUS mutations, were included in our analysis. Only 29% (10/34 patients) said they received genetic counseling. All these 10 patients received genetic counseling by their private oncologists, and none were referred to the geneticist. 79.4% (27/34 patients) are undergoing regular screening mammogram, and 32.3% (11/34 patients) are undergoing regular screening MRI breasts. 23.52% (8/34) underwent contralateral prophylactic mastectomy and 29.4% (10/34) underwent prophylactic bilateral risk reducing salpingo-oophorectomy (RRSO). All patients who underwent these surgeries did so as per the recommendation of their private oncologists, and the discussion was initiated by the oncologists themselves. 41% (14/34 patients) received Tamoxifen, and 6% (2/34 patients), received an aromatase inhibitor. 2 patients have passed away to date, both of whom had BRCA deleterious mutation. 85.3% (29/34 patients) are alive without disease, 10 of whom have BRCA deleterious mutation and 19 with VUS mutation, and 8.8% (3/34 patients) are alive with disease, two of whom have deleterious mutation and one have VUS mutation. Results for each of the deleterious and VUS mutations groups are provided below.

Conclusions: We report genetic counseling, screening and risk reducing practices on patients with BRCA deleterious mutations and mutations of unknown significance in Lebanon. All patients underwent screening mammography with or without breast MRI, except those who had bilateral mastectomies. 30% had RRSO. We will present details on ages, reproductive status and risk reduction of patients and family members. There is an urgent need for certified genetic counselors, clinics, and educational material in Lebanon as genetic counseling is still done mostly by treating oncologists.
microRNA Expression in Lebanese Breast Cancer Tissues: A Comparative and Integration Analysis

Farah J. Nassar¹, Rabih Talhouk¹, Nathalie K. Zgheib², Arafat Tfayli³, Maya El Sabban⁴, Nagi S. El Saghir³, Fouad Boulos⁵, Mark N. Jabbour⁵, Claude Chalala⁶, Rose-Mary Boustany⁷, Zhou Zhang⁸,⁹, Yinan Zheng⁸,¹⁰, Brian Joyce⁸,¹¹ Lifang Hou⁸,¹²,¹³, Ali Bazarbachi³, George Calin¹⁴, Rihab Nasr¹⁵

¹Department of Biology, Faculty of Arts and Sciences, American University of Beirut, Beirut, Lebanon
²Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
³Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
⁴Department of Biochemistry, Medical University of South Carolina, USA
⁵Department of Pathology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
⁶Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
⁷Departments of Pediatrics, Adolescent Medicine, Biochemistry and Molecular Medicine, American University of Beirut Medical Center, Beirut, Lebanon and Duke University Medical Center, Durham, NC, USA
⁸Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
⁹Driskill Graduate Program in Life Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
¹⁰Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
¹¹Division of Epidemiology/Biostatistics, School of Public Health, University of Illinois-Chicago, Chicago, IL, USA
¹²Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
¹³Department of Medicine, Center for Global Health, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
¹⁴Department of Experimental Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
¹⁵Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon

#Corresponding Author: Rihab Nasr, Ph.D.

Department of Anatomy, Cell Biology and Physiological Sciences,
Faculty of Medicine,
American University of Beirut
3 Dag Hammarskjold Plaza, Fl 8
New York, NY 10017
E-mail: rn03@aub.edu.lb
Abstract

In Lebanon, breast cancer (BC) is the most common cancer type among women, and has a higher incidence in younger patients compared to the West. microRNA (miRNA) are small noncoding RNA that act as master player at all stages of BC development. We recently showed that certain miRNA expression in Lebanese BC tissues was different than that reported in Western patients. This could reflect an ethnic difference and a necessity of global miRNA profile of Lebanese early stage BC tissues. Hence, the aim of this study is to examine miRNA expression in Lebanese BC tissues using microarray, perform comparative miRNA profile analysis with matched American samples and predict the role of dysregulated miRNA in early BC through mRNA-miRNA integration analysis. 74 miRNAs were differentially expressed in 45 tumor versus 17 normal adjacent breast tissues that were confirmed using real time PCR. Differences in dysregulated miRNA were noted in the comparative analysis that could reflect either patient age at diagnosis (miR-1288-star/3196), or ethnic variation in miRNA epigenetic regulation (miR-31/362-3p/663/329/22/373/320a/34h/196a/149/203) and sequence variation of precursor miRNA (miR-196a/185/206). mRNA profiling showed that BC samples were mainly of luminal B subtype. mRNA-miRNA integration analysis identified 719 potential mRNAs targeted by 51 miRNAs, with miR-183 and miR-182 having the highest number of targets. Integration also revealed the potential miRNA role in early BC by regulating tumor suppressive or oncogenic mRNA involved in increasing proliferation and decreasing migration and invasion. Further investigation of these dysregulated miRNA is needed to comprehend BC onset especially in young patients.
Awareness campaigns and screening for down-staging of breast cancer in Lebanon

Nagi El-Saghir, Sarah Daouk, Rita Saroufim, Nour Moukalled, Maya Charafeddine, Ali Shamseddine

Naef K. Basile Cancer Institute, Department of Internal medicine, American University of Beirut Medical Center, Beirut, Lebanon

Background: Breast cancer is the most common cancer in women in Lebanon. It constitutes 35-40% of all 4000 cancer cases seen in women in Lebanon every year. Physicians, NGOs and Lebanese Ministry of Public Health hold yearly awareness campaigns and calls for screening in October of each year, and organize awareness activities throughout the year. Evaluations of these campaigns are in progress.

Methods: We looked at statistics and staging of breast cancer at AUB and Lebanon published in the 1990s and 2000s and compared them to new statistics over the last 2 years.

Results: New data shows we still see a median age in the range of 48-50 years. There is a shift and reverse in the stages of breast cancer at presentation from advanced stages to early stages. Presently stages I and II represent around 65% of all new cases while locally advanced breast cancer represents about 35% of new cases. The number of DCIS and in-situ disease is increasing. There is a rise in the proportion of women who are treated with breast conserving surgery rather than mastectomy.

Conclusions: Awareness and screening campaigns and screening campaigns have resulted in down-staging of breast cancer in Lebanon. However, we still see a significant number of patients with locally advanced disease at presentation. More awareness and public education are needed. Study of effectiveness, community reach out, over-diagnosis and outcome are needed.
BIOGRAPHIES
Nagi S. El-Saghir, MD, FACP is Professor of Medicine and Director of Breast Center of Excellence, Naef K. Basile Cancer Institute, American University of Beirut Medical Center.

Dr. Nagi El Saghir graduated from Universite Libre de Bruxelles, completed his training in New York, and is certified by the American Boards of Internal Medicine and Medical Oncology. He is Founding President of the Lebanese Society of Medical Oncology (LSMO), Past-President of the Lebanese Society of Internal Medicine, Past-Chair of International Affairs Committee of ASCO, Co-Chair of ASCO Guidelines Advisory Group, ESMO Breast Cancer Faculty, ESO/ESMO ABC Guidelines Panel, ESMO Emerging Countries Committee, ESMO/ASCO Global Curriculum Committee and author, ASCO Global Oncology Task Force, Co-Chair of Board of the Arab Association Against Cancer, and President of the Lebanese Breast Cancer Foundation.

Prof. El Saghir has over 100 publications in peer-reviewed journals and textbooks. His research is focused on breast cancer and young women, BRCA mutations, awareness and early detection, advanced breast cancer, multidisciplinary management, guidelines and international phase III clinical trials. Co-author of ABC1, ABC2 and ABC3 Consensus Guidelines for Advanced Breast Cancer, BHGI Resource-stratified Guidelines. He is a regular speaker at Lebanese, Arab and international conferences including ASCO, ESMO, EBCC, ABC, BHGI and San Antonio as well as Pan Arab Cancer Congresses, Best of ASCO and BBCC. He serves as regular peer reviewer, Deputy Editor for The Breast (2006-2013), Editorial Board Member of The Breast, ASCO’s Journal of Global Oncology, ASCO Post and International Editor of JCO, and regular contributor to ASCO Connection.

He is author of “ABC of Breast Diseases” in Arabic and Awareness Booklet “Knowledge Road Map to Cure”. He leads major breast cancer awareness campaigns and has appeared in over 600 TV and press interviews. His research, publications, media interventions, books, and community activities, along with his colleagues, are recognized to have led to significant down-staging of breast cancer in Lebanon and improved patients’ outcome for which has received the Medal of Honor for Achievements in 2002 and the National Cedar Medal of Honor -Rank Officer (2014) from the Presidents of Lebanon, Prix 2015 du Centre National de Recherche Scientifique du Liban CNRS, awards from LSMO, AMAAC, Lebanese Order of Physicians, Cairo University, League of Womens’ Rights and others. @NagiSaghir

Speakers’ Biographies

**Matti Aapro, MD** received his medical degree from the Faculty of Medicine, University of Geneva, Switzerland. He was a fellow at the Arizona Cancer Center in Tucson and was the founding chair of the Medical and Radiation Therapy Department at the European Institute of Oncology in Milano. He is presently Dean of the Multidisciplinary Oncology Institute, Genolier, Switzerland. Dr. Aapro serves as Executive Director of the International Society for Geriatric Oncology (SIOG). He was member of the Board of the European Organization for Research and Treatment of Cancer (EORTC). Dr. Aapro is past-President of the Multinational Association for Supportive Care in Cancer (MASCC). Dr. Aapro chaired the scientific and organizing committees of UICC’s World Cancer Congress of 2008 and continues to serve UICC for the WCC in China in 2010. He was member of the ECCO/ESMO 2009 Scientific Committee. He coordinates the SPCC program of the European School of Oncology. Dr. Aapro is Editor-in-Chief of Critical Reviews in Oncology/Hematology, as well as Associate Editor of Annals of Oncology, Associate Editor for the geriatric section of the Oncologist and member of the editorial board of Journal of Clinical Oncology (breast section). He has authored more than 250 publications and his major interests are new drug development, breast cancer, cancer in the elderly and supportive care.

**Jaber Abbas, MD, FACS** is a clinical associate professor at the Department of Surgery at the American University of Beirut Medical Center. Dr. Abbas is specialized in General Surgery mainly interested in General surgical Oncology- Cancer Surgery Procedures Thyroid, Parathyroid surgery, General cancer surgery, Breast Cancer, Soft tissues. He is American Board Certified. He specialized in General Surgery and did his internship and Residency at AUBMC and his fellowships at N.Y University Medical Center and Roswell Park Memorial Institute. Research Interests: Minimally invasive parathyroid surgery Sentinel Node Biopsy

**Sandrine Atallah, MD, MHM, FECSM, ECPS** is a consultant in sexual medicine and a certified psychosexologist. She graduated as a Medical Doctor from the Saint Joseph medical Faculty (2004). She then obtained her degree in clinical sexology from René Descartes University, Paris V, Faculty of Medicine (2007). She has also qualified as a Fellow of the European Committee of Sexual Medicine (2014). She is a EFS & ESSM Certified Psycho-Sexologist (2016). Along with her private medical practice in sexology in Beirut at La Clinique du Levant and at AUBMC, she teaches Clinical Sexology at several Lebanese universities (Saint Joseph medical Faculty in Beirut and the Lebanese American University) Executive committee member (treasurer) of the MESSM (Middle East Society of Sexual Medicine: http://www.messm.org/site/), she is the chairman of its Public Awareness Committee and a member of its communication and scientific committees. She is the social media editor of the MESSM and its public website as well as the social media coeditor of the Journal of Sexual Medicine. She is a regular guest/speaker at local and international conferences and seminaries related to sexual medicine, sexual health and sexual awareness.
Sana Al Sukhun, MD, MSc is a Consultant in Medical Oncology/Hematology, mainly interested in translational research particularly development of biologic therapies targeting breast, ovarian, and gastrointestinal malignancies.

Her work focuses on advocating for greater awareness of cancer particularly breast cancer, its regional impact, and the importance of research to overcome cancer and improve health care in Jordan and the region.

Dr Al Sukhun is the president of the Jordanian Oncology Society. She is also the president of the Jordanian Society of American Medical Graduates. She is a member of International Affairs Committee of ASCO and their liaison to the Educational Committee of ASCO. She is an active member of various societies including Arab Medical Association Against Cancer (AMAAC), ESMO and many other regional and international societies. She served as Director of Breast and Gynecology Service at King Hussein Cancer Centre, and Assistant Professor of Medicine at the Department of Hematology/Oncology in the Faculty of Medicine at the University of Jordan. She has helped establish the National Breast Cancer Screening Guidelines Program in Jordan, contributed to the 2014 UICC Review of the World Health Organization’s Model List of Essential Medicines for cancer, organized & chaired the first conference on Breast Cancer in Jordan mainly focusing on "Neoadjuvant therapy", introducing the concept in the region 10 years ago, organized and chaired the first “Women Oncology Conference” in Jordan, in addition to chairing the scientific committees of other national and regional meetings.

Dr Al Sukhun earned her medical degree from the University of Jordan with honors, and pursued a Master of science, majoring in cancer biology from Wayne State University (WSU) in Michigan. She completed her internal medicine residency at Detroit Medical Centre, followed by postdoctoral research at WSU, while pursuing her fellowship in Medical Oncology & Hematology at Barbara Ann Karmanos Cancer Institute at WSU. She is board certified in internal medicine, medical Oncology & hematology.

Hamdy Azim, MD is a Professor of Clinical Oncology and immediate past chairman of the Department of Clinical Oncology, Faculty of Medicine, Cairo University. Dr Azim chairs “Kasr Al Ainy School of Oncology” KASO "which is the educational organization within the Department of Clinical Oncology, Faculty of Medicine, Cairo University.

He is the president of the Cairo Oncology Center, one of the largest private Cancer centers in the Middle East region.

Dr Azim chairs the scientific committee of the NCCN Middle East chapter and is a member of numerous societies, including the ASCO, ASH, ESMO, ASTRO and the European Blood and Marrow Transplantation Society.

He has been principal investigator for many multicenter clinical trials and has published more than 80 papers and he was the chief editor of 2 educational books (ASCO – PANARAB Lymphoma Conference (1999) and the MD Anderson Cancer Centre / Cairo University joint meeting (2006).

Hatem A. Azim Jr. MD is a medical oncologist, completed his medical training at the National Cancer Institute in Cairo before joining the Jules Bordet Institute in Brussels in 2009 where he worked for 7 years. He holds a Master’s Degree from University of Newcastle Upon Tyne and a PhD from the Faculty of Medicine at the Université Libre de Bruxelles (ULB). He is highly published mostly in the field of breast cancer in young women with more than 100 published manuscripts. He also served as an invited speaker in all major oncology conferences, notably ASCO, and ESMO. He recently joined a French R&D Biotech to guide the clinical development of 2nd generation immune check-point inhibitors across different tumor types.

Fouad Boulos, MD graduated with an MD from AUB in 2001, following which he spent an internship year in anatomic pathology at AUBMC. Then, he joined the anatomic and clinical pathology residency program (2002-06) at Vanderbilt University Medical Center in Nashville, Tennessee. This was immediately followed by a 15-month surgical pathology fellowship at the same institution with Dr. David Page, a leading figure in surgical pathology, particularly breast pathology. Dr. Boulos is certified by the American Board of Anatomic and Clinical Pathology. Dr. Boulos' research interests include the epidemiology of breast cancer in Lebanon, as well as atypical and premalignant breast lesions, and sentinel lymph node biopsy, among others.
Mahmoud El-Tamer, MD is trained as a breast surgeon with 25 years of experience caring for patients with breast cancer, and works collaboratively with other breast cancer specialists on Memorial Sloan-Kettering Cancer Center’s multidisciplinary breast cancer disease management team. Dr. El-Tamer received his MD from the American University of Beirut in 1981. He completed his residency at the American University of Beirut Medical Center in 1985, followed by four years of surgical oncology and reconstructive surgery at Memorial Sloan-Kettering Cancer Center. After his training, Dr. El-Tamer became interested in joining these two disciplines to provide improved care to breast cancer patients, and has developed a special expertise in this growing field of oncoplastic surgery.

Dr. El-Tamer’s research interests have covered different aspects of breast cancer and quality of care in surgery. He has been the principal or co-principal investigator on research grants from the Avon Breast Cancer Foundation, the United States Veterans’ Administration, and the American College of Surgeons. His current research interests are focused on tumor micro-environment post mastectomy radiation in 1–3 positive nodes and breast conservation. Dr. El-Tamer has recently published “Principals & Techniques in Oncoplastic Breast Cancer Surgery”, a textbook to help other surgeons enhance cosmetic results while performing surgery to treat breast cancer. Dr. El-Tamer holds the patent to a new agent for sentinel node detection.

Chantal Farra, MD, following four years of residency in Medical Genetics at Aix-Marseille and René Descartes, Paris V Universities, France, Dr Chantal Farra pursued fellowship training in Molecular Cytogenetics at the Brigham and Women’s Hospital (BWH-Harvard) in Boston, USA. She was recruited to AUBMC in 2007 and was appointed Director of Medical Genetics. She established and developed many projects at AUBMC including Familial Breast and/or Ovarian Cancer Genetic Screening and Counseling. She is the author and co-author of several peer reviewed articles and a member of several professional genetics associations.

Fady Geara, MD, PhD is a Professor and Chairman at the Department of Radiation Oncology and the Founding Director of The Naef K Basile Cancer Institute (2007-2012) at the American University of Beirut Medical Center, Beirut, Lebanon Education 1994 American Board of Radiology; Radiation Oncology 1993 University of Paris XI, France, Ph.D. in Radiation Biology (Research conducted at MDACC, Houston TX) 1989-93 Clinical and research fellowship in radiation oncology; The University of Texas MD Anderson Cancer Center, Houston USA 1990 University of Tours, France, Radiation Oncology Diploma. 1989 University of Paris XI, France, Masters of Science Degree in Radiobiology. 1985 University of Paris XI, France, Medical Doctor Degree Academic Experience & Service • Assistant Professor, Department of Radiation Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas, 1994-97. • Faculty Associate, Department of Radiation Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas, 1993-94. • Clinical Fellow, Radiation Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston TX, 1991-93. • Visiting Scientist, Experimental Radiation Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston TX, 1989-91. • Resident in Radiation Oncology, at the Institut Gustave Roussy (Villejuif), University Hospital Henri Mondor (Creteil), and University Hospital Bretonneau (Tours), France, 1985-89. Board Certifications American Board of Radiology; Radiation Oncology Question item writer for the American Board written examination (1996-1997) Areas of Interest Clinical Interest: General Radiation Oncology, Radiation Biology Procedures: Conformal 3D Radiation therapy, Stereotactic radiosurgery and Radiotherapy; High dose rate brachytherapy.
Marwan Ghosn, MD, acquired his medical degree and his post graduate expertise in Hematology and Oncology from Saint-Joseph University, Faculty of Medicine, in Beirut, Lebanon as well as from the University of Paris XI – Kremlin-Bicêtre and Institut Gustave Roussy Cancer Center in France. He is Chairman of the Hematology & Oncology Department and former Chairman of the Public Health department at Saint-Joseph University, Faculty of Medicine in Beirut, Lebanon. He acquired a Master in Hospital and Health Management from The Higher School of Business, ESA, in Beirut and a Master in the Quality Management of Units for Care Production (MUPS) from the University of Paris VII, Denis Diderot, France.

He is currently the Director of the Cancer Center at Clemenceau Medical Center, affiliated with Johns Hopkins International in Beirut.

Professor Ghosn has also served, for more than 15 years, as Chairman of the Hematology-Oncology Department at Hotel-Dieu de France University Hospital in Beirut, where he is also currently continuing his clinical, medical and research activities. He served as President of the Lebanese Society of Medical Oncology (LSMO) and was member of the Board of the Lebanese Cancer Society (LCS) for many years. He is an active member of several National & International Scientific Organizations and Societies including the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), the European Society of Medical Oncology (ESMO), the American Society of Hematology (ASH), The European Hematology Association (EHA), the International Society of Geriatric Oncology (SIOG), Francophone d’Oncologue Médicale (FOM) and Société Franco Méditerranéenne de Cancer (SFMC).

He has also been very active as member of the Arab Medical Association Against Cancer (AMAAC). He has served on the Executive Board as representative for Lebanon for many years and was the founding Editor in Chief of the Pan Arab Journal of Oncology (PAJO). He had also active contribution to its scientific activities being Chairman and/or member of the Scientific Committee of multiple Pan Arab Cancer Congresses. He is author and co-author of more than 100 peer-reviewed articles. He also published and gave an extensive number of communications, posters and abstracts at regional and international meetings, as well as several chapters in books in the field of Medical Oncology and Health Care Management. He has also served as Editor-in-Chief of the “Cancer Letter” edited by the Lebanese Cancer Society.

Professor Ghosn has special interests in multiple areas including leadership in conducting research and clinical trials in multiple solid tumors. He has an expertise in breast cancer, urologic cancers, gastrointestinal tumors, geriatric oncology domain as well as in patients’ safety and Quality in Healthcare.

Ziad Hamdan, EMBA is an independent consultant in strategy and management with more than 12 years of international experience mainly in the telecommunication and media. He has recently joined Allianz SNA group in Lebanon to develop the Bancassurance business in Lebanon and the region.

On top of his consulting services, Ziad has conducted several workshops and seminars on strategy and management and has partnered with ESA to promote and develop executive education.

Ziad holds an Engineering degree delivered by INSA (France) and an Executive MBA from the ESA. Ziad is a proud active member of the Lebanese Breast Cancer Foundation.
Imad Kaddoura, MD has graduated as a fully trained General Surgeon from the Department of Surgery at the American University of Beirut in July 1983. That same year, he joined the Division of Plastic and Reconstructive Surgery at the University of Toronto and attained his certification on June 1987. On July 1987 he joined the Department of Surgery – Faculty of Medicine at the American University of Beirut in his capacity as an Assistant Professor of Plastic Surgery. On January 8, 1988, he established the training program in Plastic and Reconstructive Surgery at the American University of Beirut which he chaired for 23 years. Dr. Kaddoura has more than thirty peer reviewed publications in Plastic and Reconstructive Surgery. He is a member of many American and Canadian Plastic Surgery Societies, Past President of the American College of Surgeons (Lebanon Chapter) and currently a member at the Division of Plastic and Reconstructive Surgery at AUBMC with a diverse Cosmetic and Plastic Surgery Practice.

Nagi Khouri, MD is the inaugural Carol Ann Flanagan Professor in Breast Imaging at Johns Hopkins University and is an Associate Professor of Radiology and Oncology. He is a nationally and internationally recognized pioneer who is largely responsible for advancing the science of breast imaging into a full-fledge specialty in Radiology. After receiving his medical degree from the American University of Beirut, he completed his residency training in Diagnostic Radiology at AUB and Johns Hopkins. He subsequently joined the Johns Hopkins faculty and soon after was appointed as the director of the Chest Service. What followed was the decision to focus the next phase of his career on the care of women to increase awareness and early detection of breast cancer. Very soon after, Dr. Khouri introduced the concept of the dedicated breast specialist in radiology. He served as the Director of Breast Imaging for a decade and was integrally involved in the creation of the Johns Hopkins Comprehensive Breast Center, a model of patient-centered, multi-disciplinary care for breast cancer patients that has been replicated all over the world.

Dr. Khouri has published extensively, authoring several book chapters and 49 peer-reviewed articles. He has also served as a mentor to numerous fellows, residents and medical students across disciplines. Dr. Khouri is a strong advocate for expanding Johns Hopkins’ wealth of intellectual resources throughout the world. He takes exceptional pride in establishing an educational exchange between AUB and Johns Hopkins. The exchange contributed to the successful careers of several physician-scientists who are practicing in Lebanon and the region in multiple disciplines. Dr. Khouri now dedicates considerable time to international outreach activities. He is widely sought as an advisor to governments and health care organizations, particularly in the Middle East, on the design and operations of multidisciplinary breast programs and breast health facilities.
Mothaffar F. Rimawi, M.D. is an Associate Professor of Medicine, the Medical Director of the Lester and Sue Smith Breast Center, and co-Leader of the Breast Cancer Research program of the Dan L Duncan Comprehensive Cancer Center (DLDCCC) at Baylor College of Medicine. He is also the Chief of Breast Oncology at Ben Taub General Hospital and Smith Specialty Clinic. He received his medical degree from the University of Jordan School of Medicine and completed his training in Internal Medicine, Medical Oncology, and Breast Oncology at Baylor College of Medicine.

His research interest is in translating laboratory findings into the clinic. His focus is on designing and conducting biologically rational, biospecimen-intense clinical trials, and studying biomarkers of response and resistance on human samples. This approach helps elucidate mechanisms of therapeutic resistance to design more tailored treatment approaches, and identify a treatment de-escalation strategy to spare patients unnecessary toxicity and cost when possible, without compromising outcomes.

Dr. Rimawi has designed, led, and reported multiple prominent national and international trials in breast cancer with special focus on translational work in HER2+ and in ER+ breast cancer. His work helped promote dual HER2 inhibition, concurrent targeting of ER and He serves on multiple national clinical research leadership committees including the Breast Committee of the NRG Oncology Group and is co-Chair of the HER2 Working group of the Translational Breast Cancer Symposium (TBCRC).

Ali Shamseddine, MD is a professor of clinical specialty of Hematology/Oncology at the Department of Internal Medicine at the American University of Beirut Medical Center. His Clinical Interests are in Gastrointestinal, breast and lung cancers. Dr. Shamseddine is Board Certified. He Graduated from Alexandria University in Egypt and pursued his Internship in Internal Medicine and did his residency in Radiotherapy at Alexandria University and in Internal Medicine at American University of Beirut (MGH affiliation) and Fellowship in Hematology / Oncology at American University of Beirut. Dr. Shamseddine Research Interests are in new combination chemotherapy, Pancreatic Cancer, Breast Cancer, Lung Cancer and Epidemiology of Cancer.
SAVE THE DATE

6th Beirut Breast Cancer Conference

(BBCC 6)

FEBRUARY 08 – 10, 2018

BEIRUT, LEBANON
Contact Information

For more information about this activity, please contact:

Continuing Medical Education (CME) Office  
American University of Beirut Medical Center  
P.O. Box 11-236 Riad El Solh  
Beirut 1107 2020, Lebanon  
Tel: +961-1-350 000 ext. 4752 – 4718; Fax: +961-1-744 467  
Email: cme@aub.edu.lb  
Web: http://cme.aub.edu.lb